UNSPSC 51172124: Difenoximide or difenoximide hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C32H31N3O4 and C32H31N3O4.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers 8UG1323C03 and 6GEY4W769K, the base compound being chemically known as 4-(((2,5-dioxo-1-pyrrolidinyl)oxy)carbonyl)-alpha,alpha,4-triphenyl-1-piperidinebutanenitrile but generally known as difenoximide, which bears US NIH Compound Identifier 39481.

UNSPSC 51172124 Difenoximide or difenoximide hydrochloride is a Commodity code that captures active pharmaceutical ingredients and finished drug products procured by state and local health, corrections, and pharmacy benefit programs. The recent opportunities show state and local jurisdictions sourcing drug-testing services, therapeutic pharmacy programs, and multi-source generic pharmaceuticals through cooperative purchasing vehicles and direct RFPs. The issuing bodies span state health and human services commissions, county corrections departments, and multistate cooperative purchasing alliances, indicating that demand runs across clinical, correctional, and procurement-support functions rather than concentrating in a single agency type.

Texas dominates the recent activity: the Texas Health and Human Services Commission issued an RFI in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs, and Collin County Community Supervision and Corrections Department posted an RFP (2026-327) due July 23, 2026 for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year initial term plus three optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, drawing participation from multiple states including Oregon. The Collin County RFP explicitly covers immunoassay screening and LC/MS/MS or GC/MS confirmation methodologies, SAMHSA and state-level lab certifications, and per-test pricing with annual volumes near 25,000 tests across five-panel and six-panel screens. The MMCAP RFP requires vendors to work through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), certify cGMP and DSCSA compliance, maintain insurance thresholds including $5 million commercial general liability, and price competitively on a two-year term effective July 1, 2026.